Search

Displaying results 6541 - 6550 of 10000 in total
  1. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis

  2. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  3. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  4. Drug

    Utatrectinib

    go.drugbank.com/drugs/DB21295
    Investigational

    Utatrectinib has a monoisotopic molecular weight of 382.17 Da. … Utatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Utatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.

  5. Drug

    Etofamide

    go.drugbank.com/drugs/DB13258
    Approved

    Etofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].

  6. Drug

    Captodiame

    go.drugbank.com/drugs/DB09014
    Experimental

    Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine.

  7. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. … Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.

    Categories: Adenosine A receptor agonists, Adenosine A2 Receptor Agonists
  8. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

  9. Drug

    Bevurogant

    go.drugbank.com/drugs/DB21507
    Experimental

    Bevurogant has a monoisotopic molecular weight of 532.2 Da. … The usage of the INN stem '-rogant' in the name indicates that Bevurogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and inverse agonist.

  10. Drug

    Isospaglumic acid

    go.drugbank.com/drugs/DB19650
    Investigational

    Isospaglumic acid has a monoisotopic molecular weight of 304.09 Da. … Isospaglumic acid is a small molecule drug.